ReviewBMC medicine2020
The dynamic wound microbiome.
Review in BMC medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- S1 Guideline on Infected Interdigital Intertrigo (also called Gram-Negative Toe Web Infection).Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Guideline
- Review
- The dual role of the microbiome in chronic wound management.Cell communication and signaling : CCS · 2026Review
- Biofilm-Host Immune Crosstalk at the Diabetic Foot Ulcer Interface: Molecular Mechanisms, Immune Evasion, and Next-Generation Anti-Biofilm Strategies.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- A longitudinal profiling of microbiome of diabetic foot ulcers shows functional role of microbial communities in wound worsening and chronicity.Current research in microbial sciences · 2026Article
- Emerging Biomedical Engineering Therapies for Infected Diabetic Foot Ulcers: Toward Antibacterial Functionalization and Pathology-Responsive Regulation.Small science · 2026Review
- Anaerobe-associated microbial shifts at infection onset in diabetes-related foot ulcers revealed by longitudinal metagenomics.Frontiers in cellular and infection microbiology · 2026Article
- Analysis of pathogen distribution and association with lipid levels in patients with diabetic foot.Frontiers in medicine · 2026Article
- Rapid and low-cost detection of six major pediatric enteric pathogens using a closed-tube PCR-invasive reaction assay.Frontiers in cellular and infection microbiology · 2026Article
- Fluorescence-Based In Vitro Detection of Wound-Associated Bacteria with a Handheld Imaging System.Diagnostics (Basel, Switzerland) · 2025Article
- Curcumin-Loaded Drug Delivery Systems for Acute and Chronic Wound Management: A Review.Bioengineering (Basel, Switzerland) · 2025Review
- Exploring the Microbiome of Diabetic Foot Ulcers: A Focus on Cases with a Clinical Worse Outcome.Antibiotics (Basel, Switzerland) · 2025Article
- Application of metagenomic next-generation sequencing (mNGS) to describe the microbial characteristics of diabetic foot ulcers at a tertiary medical center in South China.BMC endocrine disorders · 2025Article
- In vitro evaluation of silver-zinc oxide-eugenol nanocomposite for enhanced antimicrobial and wound healing applications in diabetic conditions.Discover nano · 2025Article
- Management of diabetic foot ulcers: polyherbal formulations and novel delivery systems for herbal active components.Frontiers in pharmacology · 2025Review
- Anaerobes in diabetic foot infections: pathophysiology, epidemiology, virulence, and management.Clinical microbiology reviews · 2024Review
- Sequence analysis of microbiota in clinical human cases with diabetic foot ulcers from China.Heliyon · 2024Article
- Prokaryotic and eukaryotic skin microbiota modifications triggered by Leishmania infection in localized Cutaneous Leishmaniasis.PLoS neglected tropical diseases · 2024Article
- A Systematic Review of the Microbial Landscape of Diabetic Foot Ulcers in Uganda.Infection and drug resistance · 2024Review
- Mesenchymal stem cells-based drug delivery systems for diabetic foot ulcer: A review.World journal of diabetes · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundDiabetic foot ulcers (DFUs) account for the majority of all limb amputations and hospitalizations due to diabetes complications. With 30 million cases of diabetes in the USA and 500,000 new diagnoses each year, DFUs are a growing health problem. Diabetes patients with limb amputations have high postoperative mortality, a high rate of secondary amputation, prolonged inpatient hospital stays, and a high incidence of re-hospitalization. DFU-associated amputations constitute a significant burden on healthcare resources that cost more than 10 billion dollars per year. Currently, there is no way to identify wounds that will heal versus those that will become severely infected and require amputation. MAIN BODY: Accurate identification of causative pathogens in diabetic foot ulcers is a critical component of effective treatment. Compared to traditional culture-based methods, advanced sequencing technologies provide more comprehensive and unbiased profiling on wound microbiome with a higher taxonomic resolution, as well as functional annotation such as virulence and antibiotic resistance. In this review, we summarize the latest developments in defining the microbiology of diabetic foot ulcers that have been unveiled by sequencing technologies and discuss both the future promises and current limitations of these approaches. In particular, we highlight the temporal patterns and system dynamics in the diabetic foot microbiome monitored and measured during wound progression and medical intervention, and explore the feasibility of molecular diagnostics in clinics.
conclusionMolecular tests conducted during weekly office visits to clean and examine DFUs would allow clinicians to offer personalized treatment and antibiotic therapy. Personalized wound management could reduce healthcare costs, improve quality of life for patients, and recoup lost productivity that is important not only to the patient, but also to healthcare payers and providers. These efforts could also improve antibiotic stewardship and control the rise of "superbugs" vital to global health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.